New pill for cystic fibrosis moves to human testing

NCT ID NCT05090904

Completed Disease control Sponsor: Insmed Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental pill called brensocatib in 29 adults with cystic fibrosis. The main goals were to see how the drug behaves in the body and whether it is safe compared to a placebo over 4 weeks. Participants took the pill once daily, and researchers measured drug levels and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brensocatib (also called INS1007) oral tablet
What this could lead to: If successful, this could point toward a new treatment option to help control cystic fibrosis lung disease.
What could go wrong: This is a small, early-phase trial focused on safety and drug levels, not on whether the drug improves symptoms. Many drugs fail in later, larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

USA001

Gainesville, Florida, 32610, United States
USA002

St Louis, Missouri, 63101, United States
USA003

Tyler, Texas, 75708, United States
USA004

Dallas, Texas, 75390, United States
USA006

Cleveland, Ohio, 44195, United States
USA008

Cleveland, Ohio, 44106, United States
USA009

Charleston, South Carolina, 29425, United States
USA011

Boston, Massachusetts, 02115, United States
USA016

Augusta, Georgia, 30912, United States
USA017

Nashville, Tennessee, 37232, United States
USA018

Portland, Oregon, 97239, United States
USA022

New York, New York, 10032, United States
USA023

Ann Arbor, Michigan, 48109, United States
USA025

Glenview, Illinois, 60025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.